Cargando…

Multiple sclerosis

Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Klocke, Shilpa, Hahn, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881109/
https://www.ncbi.nlm.nih.gov/pubmed/31857931
http://dx.doi.org/10.9740/mhc.2019.11.349
_version_ 1783473884027158528
author Klocke, Shilpa
Hahn, Nicole
author_facet Klocke, Shilpa
Hahn, Nicole
author_sort Klocke, Shilpa
collection PubMed
description Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of multiple sclerosis. Disease-modifying therapies are now being classified into categories based on level of efficacy. Strategies to use disease-modifying therapies earlier and in a more customizable manner are also emerging. A clinical case study will be used throughout this pearl to review the disease-modifying therapies and use patient-specific factors to develop and provide recommendations on therapeutic strategies for individuals with relapsing forms of multiple sclerosis.
format Online
Article
Text
id pubmed-6881109
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher College of Psychiatric & Neurologic Pharmacists
record_format MEDLINE/PubMed
spelling pubmed-68811092019-12-19 Multiple sclerosis Klocke, Shilpa Hahn, Nicole Ment Health Clin Psychopharmacology Pearls Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of multiple sclerosis. Disease-modifying therapies are now being classified into categories based on level of efficacy. Strategies to use disease-modifying therapies earlier and in a more customizable manner are also emerging. A clinical case study will be used throughout this pearl to review the disease-modifying therapies and use patient-specific factors to develop and provide recommendations on therapeutic strategies for individuals with relapsing forms of multiple sclerosis. College of Psychiatric & Neurologic Pharmacists 2019-11-27 /pmc/articles/PMC6881109/ /pubmed/31857931 http://dx.doi.org/10.9740/mhc.2019.11.349 Text en © 2019 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Psychopharmacology Pearls
Klocke, Shilpa
Hahn, Nicole
Multiple sclerosis
title Multiple sclerosis
title_full Multiple sclerosis
title_fullStr Multiple sclerosis
title_full_unstemmed Multiple sclerosis
title_short Multiple sclerosis
title_sort multiple sclerosis
topic Psychopharmacology Pearls
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881109/
https://www.ncbi.nlm.nih.gov/pubmed/31857931
http://dx.doi.org/10.9740/mhc.2019.11.349
work_keys_str_mv AT klockeshilpa multiplesclerosis
AT hahnnicole multiplesclerosis